Transition Bio
PrivateLast Round
Series B
Oct 30, 2024
Total Funding Raised
$72.3M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Transition Bio is a biotechnology company that develops a hypothesis-free drug discovery and diagnostics platform utilizing droplet microfluidic techniques and protein biophysics to analyze biomolecular condensates.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Medical AI
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Transition Bio Comparables
Compare Transition Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Nereid Therapeutics | 87% | |
| Dewpoint Therapeutics | 86% | |
| Medusa Therapeutics Limited | 83% |
Transition Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Oct 30, 2024 | ||||
| Seed Round | Jan 10, 2024 | ||||
| Series A | Jun 2, 2022 | ||||
| Seed | Sep 1, 2020 |
Transition Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Magnetic Ventures | Series A |
| Magnetic Ventures | Series A, Series B |
| Taiho Ventures | Series A |
| Lifeforce Capital | Series A, Series B, Seed |
| Northpond Ventures | Series A |
| Cambridge Enterprise | Seed, Series A |
| Northpond Ventures | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors increased 72% MoM, reaching 2.9K.
- Mar 27, 2026
Close affiliation disclosed with University of Cambridge and Harvard.
Transition Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Transition Bio's valuation, stock price, and market status.
Is Transition Bio a public or private company?
Transition Bio is a private company.
What is the current stock price of Transition Bio?
Transition Bio is a private company with no public stock price. No recent secondary market data is available.
How much is Transition Bio worth (valuation)?
Valuation information for Transition Bio is not publicly available.
Can I buy Transition Bio stock?
Transition Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Transition Bio's last funding round?
Transition Bio's most recent funding round was Series B on October 30, 2024.
Who are the main investors in Transition Bio?
Key investors in Transition Bio include Lifeforce Capital, Northpond Ventures.
Will Transition Bio IPO soon?
No public IPO plans have been announced for Transition Bio.
How can I track Transition Bio secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Transition Bio's secondary market activity and sign up for updates.